Multidisciplinary Treatment of Primary Melanoma

Katharine Yao, Glen Balch, David J. Winchester

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.

Original languageEnglish (US)
Pages (from-to)267-281
Number of pages15
JournalSurgical Clinics of North America
Volume89
Issue number1
DOIs
StatePublished - Feb 2009

Fingerprint

Melanoma
Interferons
Lymph Node Excision
Vaccines
T-Lymphocytes
Therapeutics
Research

Keywords

  • Breslow thickness
  • Immunotherapy
  • Interferon
  • Melanoma
  • Melanoma vaccine
  • Sentinel node
  • Thin melanomas

ASJC Scopus subject areas

  • Surgery

Cite this

Multidisciplinary Treatment of Primary Melanoma. / Yao, Katharine; Balch, Glen; Winchester, David J.

In: Surgical Clinics of North America, Vol. 89, No. 1, 02.2009, p. 267-281.

Research output: Contribution to journalArticle

Yao, Katharine ; Balch, Glen ; Winchester, David J. / Multidisciplinary Treatment of Primary Melanoma. In: Surgical Clinics of North America. 2009 ; Vol. 89, No. 1. pp. 267-281.
@article{e51ddacea2a14d97962120ef1497102f,
title = "Multidisciplinary Treatment of Primary Melanoma",
abstract = "This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.",
keywords = "Breslow thickness, Immunotherapy, Interferon, Melanoma, Melanoma vaccine, Sentinel node, Thin melanomas",
author = "Katharine Yao and Glen Balch and Winchester, {David J.}",
year = "2009",
month = "2",
doi = "10.1016/j.suc.2008.11.002",
language = "English (US)",
volume = "89",
pages = "267--281",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Multidisciplinary Treatment of Primary Melanoma

AU - Yao, Katharine

AU - Balch, Glen

AU - Winchester, David J.

PY - 2009/2

Y1 - 2009/2

N2 - This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.

AB - This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.

KW - Breslow thickness

KW - Immunotherapy

KW - Interferon

KW - Melanoma

KW - Melanoma vaccine

KW - Sentinel node

KW - Thin melanomas

UR - http://www.scopus.com/inward/record.url?scp=58749097828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749097828&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2008.11.002

DO - 10.1016/j.suc.2008.11.002

M3 - Article

C2 - 19186240

AN - SCOPUS:58749097828

VL - 89

SP - 267

EP - 281

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 1

ER -